Probucol inhibited Nox2 expression and attenuated podocyte injury in type 2 diabetic nephropathy of db/db mice

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 12, 2013, Pages 1883-1890

  Zhou, Guangyu ^a   Wang, Yanqiu ^a   He, Ping ^a   Li, Detian ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Oxidative stress; Podocyte; Probucol

Indexed keywords

ALBUMIN; COLLAGEN TYPE 4; FIBRONECTIN; GLUCOSE; NEPHRIN; PROBUCOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; THIOBARBITURIC ACID REACTIVE SUBSTANCE; WT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; BODY WEIGHT; CELL DAMAGE; CELL LOSS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE COURSE; DOWN REGULATION; DRUG MECHANISM; EXPERIMENTAL MOUSE; EXTRACELLULAR MATRIX; GLOMERULUS; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; KIDNEY CORTEX; KIDNEY MASS; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; PROTEIN EXPRESSION; RENAL PROTECTION; TREATMENT DURATION; URINE LEVEL;

ALBUMINURIA; ANIMALS; ANTIOXIDANTS; COLLAGEN TYPE IV; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FIBRONECTINS; KIDNEY DISEASES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE; MICE, MUTANT STRAINS; NADPH OXIDASE; PODOCYTES; PROBUCOL; WT1 PROTEINS;

EID: 84892624146     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00634     Document Type: Article

References (49)

1. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int., 74, 22-36 (2008).
2. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care, 30 (Suppl. , S4-S41 (2007).
3. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes, 57, 1446-1454 (2008).
4. Han SY, So GA, Jee YH, Han KH, Kang YS, Kim HK, Kang SW, Han DS, Han JY, Cha DR. Effect of retinoicacid in experimental diabetic nephropathy. Immunol. Cell Biol., 82, 568-576 (2004).
5. Bird JE, Milhoan K, Wilson CB, Young SG, Mundy CA, Parthasarathy S, Blantz RC. Ischemic acute renal failure and antioxidant therapy in rat. The relation between glomerular and tubular dysfunction. J. Clin. Invest., 81, 1630-1638 (1988).
6. Dage RC, Anderson BA, Mao SJ, Koerner JE. Probucol reduced myocardial dysfunction during reperfusion after short-term ischemia in rabbit heart. J. Cardiovasc. Pharmacol., 17, 158-165 (1991).
7. Dujovne CA, Harris WS, Gerrond LL, Fan J, Muzio F. Comparison of effects of probucol versus vitamin E on ex vivo oxidation susceptibility of lipoproteins in hyperlipoproteinemia. Am. J. Cardiol., 74, 38-42 (1994).
8. Gotoh N, Shimizu K, Komuro E, Tsuchiya J, Noguchi N, Niki E. Antioxidant activities of probucol against lipid peroxidations. Biochim. Biophys. Acta, 1128, 147-154 (1992).
9. Kondo S, Shimizu M, Urushihara M, Tsuchiya K, Yoshizumi M, Tamaki T, Nishiyama A, Kawachi H, Shimizu F, Quinn MT, Lambeth DJ, Kagami S. Addition of the antioxidant probucol to angiotensin II type I receptor antagonist arrests progressive mesangioproliferative glomerulonephritis in the rat. J. Am. Soc. Nephrol., 17, 783-794 (2006).
10. Agardh CD, Stenram U, Torffvit O, Agardh E. Effects of inhibition of glycation and oxidative stress on the development of diabetic nephropathy in rats. J. Diabetes Complications, 16, 395-400 (2002).
11. Endo K, Miyashita Y, Sasaki H, Ohira M, Saiki A, Koide N, Otsuka M, Oyama T, Takeyoshi M, Ito Y, Shirai K. Probucol delays progression of diabetic nephropathy. Diabetes Res. Clin. Pract., 71, 156-163 (2006).
12. Hummel KP, Dickie MM, Coleman DL. Diabetes, a new mutation in the mouse. Science, 153, 1127-1128 (1966).
13. Jia ZH, Liu ZH, Zheng JM, Zeng CH, Li LS. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/ db mice. Exp. Clin. Endocrinol. Diabetes, 115, 571-576 (2007).
14. Perkins BA, Ficociello LH, Ostrander BE, Silva KH, Weinberg J, Warram JH, Krolewski AS. Microalbuminuria and the risk for early progressive renal function decline in type1 diabetes. J. Am. Soc. Nephrol., 18, 1353-1361 (2007).
15. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin dependent patients. N. Engl. J. Med., 311, 89-93 (1984).
16. Viberti GC, Jarrett RJ, Mahmud U, Hill RD, Argyropoulos A, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet, 1, 1430-1432 (1982).
17. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal diseases: a meta-analysis. Kidney Int., 59, 260-269 (2001).
18. Franceschini G, Werba JP, Calabresi L. Drug control of reverse cholesterol transport. Pharmacol. Ther., 61, 289-324 (1994).
19. Zhong JK, Guo ZG, Li C, Wang ZK, Lai WY, Tu Y. Probucol alleviates atherosclerosis and improves high density lipoprotein function. Lipids Health Dis., 10, 210 (2011).
20. Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, Kashiwagi S, Hayashi J. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. J. Am. Coll. Cardiol., 39, 610-616 (2002).
21. Yokoi H, Daida H, Kuwabara Y, Nishikawa H, Takatsu F, Tomihara H, Nakata Y, Kutsumi Y, Ohshima S, Nishiyama S, Seki A, Kato K, Nishimura S, Kanoh T, Yamaguchi H. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: The probucol angioplasty restenosis trial. J. Am. Coll. Cardiol., 30, 855-862 (1997).
22. Fukuda M, Ikegami H, Kawaguchi Y, Sano T, Ogihara T. Antioxidant, probucol, can inhibit the generation of hydrogen peroxide in islet cells induced by macrophages and prevent islet cell destruction in NOD mice. Biochem. Biophys. Res. Commun., 209, 953-958 (1995).
23. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet, 352, 213-219 (1998).
24. Ziyadeh FN. Mediators of diabetic renal disease: the case for tgfbeta as the major mediator. J. Am. Soc. Nephrol., 15 (Suppl. , S55-S57 (2004).
25. Cohen MP, Lautenslager GT, Shearman CW. Increased urinary type IV collagen marks the development of glomerular pathology in diabetic db/db mice. Metabolism, 50, 1435-1440 (2001).
26. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. U.S.A., 97, 8015-8020 (2000).
27. Cooper ME, Boner G, Cao Z, Kawachi H, Bonnet F, Allen TJ. Irbesartan normalizes the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia, 44, 874-877 (2001).
28. Ruotsalainen V, Ljungberg P, Wartiovaara J, Lenkkeri U, Kestilä M, Jalanko H, Holmberg C, Tryggvason K. Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc. Natl. Acad. Sci. U.S.A., 96, 7962-7967 (1999).
29. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr. Diabetes Rev., 4, 39-45 (2008).
30. Ichinose K, Maeshima Y, Yamamoto Y, Kinomura M, Hirokoshi K, Kitayama H, Takazawa Y, Sugiyama H, Yamasaki Y, Agata N, Makino H. 2-(8-Hydroxy-6-methoxy-1- oxo-1H-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes, 55, 1232-1242 (2006).
31. Menne J, Park JK, Shushakova N, Mengel M, Meier M, Fliser D. The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury. J. Am. Soc. Nephrol., 18, 2046-2053 (2007).
32. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature, 414, 813-820 (2001).
33. Rösen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab. Res. Rev., 17, 189-212 (2001).
34. Ha H, Hwang IA, Park JH, Lee HB. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res. Clin. Pract., 82 (Suppl. , S42-S45 (2008).
35. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res., 86, 494-501 (2000).
36. Lassègue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol., 285, R277-R297 (2003).
37. Radeke HH, Meier B, Topley N, Floge J, Habermehl GG, Resch K. Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells. Kidney Int., 37, 767-775 (1990).
38. Jones SA, Hancock JT, Jones OT, Neubauer A, Topley N. The expression of NADPH oxidase components in human glomerular mesangial cells: Detection of protein and mRNA for p47phox, p67phox, and p22phox. J. Am. Soc. Nephrol., 5, 1483-1491 (1995).
39. Gorin Y, Ricono JM, Kim NH, Bhandari B, Choudhury GG, Abboud HE. Nox4 mediates angiotensin II-induced activation of Akt/ protein kinase B in mesangial cells. Am. J. Physiol. Renal Physiol., 285, F219-F229 (2003).
40. Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes, 55, 225-233 (2006).
41. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev., 87, 245-313 (2007).
42. Geiszt M, Kopp JB, Varnai P, Leto TL. Identification of renox, an NAD(P)H oxidase in kidney. Proc. Natl. Acad. Sci. U.S.A., 97, 8010-8014 (2000).
43. Shiose A, Kuroda J, Tsuruya K, Hirai M, Hirakata H, Naito S, Hattori M, Sakaki Y, Sumimoto H. A novel superoxide-producing NAD(P)H oxidase in kidney. J. Biol. Chem., 276, 1417-1423 (2001).
44. Asaba K, Tojo A, Onozato ML, Goto A, Quinn MT, Fujita T, Wilcox CS. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int., 67, 1890-1898 (2005).
45. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LM, Jerums G, Osicka TM. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes, 51, 3274-3282 (2002).
46. Gorin Y, Block K, Hernandez J, Bhandari B, Wagner B, Barnes JL, Abboud HE. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J. Biol. Chem., 280, 39616-39626 (2005).
47. Satoh M, Fujimoto S, Haruna Y, Arakawa S, Horike H, Komai N, Sasaki T, Tsujioka K, Makino H, Kashihara N. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am. J. Physiol. Renal Physiol., 288, F1144-F1152 (2005).
48. Etoh T, Inoguchi T, Kakimoto M, Sonoda N, Kobayashi K, Kuroda J, Sumimoto H, Nawata H. Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocininduced diabetic rats and its reversibility by interventive insulin treatment. Diabetologia, 46, 1428-1437 (2003).
49. Sedeek M, Gutsol A, Montezano AC, Burger D, Nguyen Dinh Cat A, Kennedy CR, Burns KD, Cooper ME, Jandeleit-Dahm K, Page P, Szyndralewiez C, Heitz F, Hebert RL, Touyz RM. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of type 2 diabetes. Clin. Sci., 124, 191-202 (2013).